Axogen, Inc.
AXGNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Axogen, Inc. focuses on Medical Devices services and products. Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. Valued at $2.10B, AXGN is a mid-cap name in its sector. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Market Cap
$2.10B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
54.21
EPS (TTM)
$-0.64
EPS (Fwd)
$0.73
ROE
-18.0%
ROA
-2.3%
Cash
$101.6M
Total Debt
$20.6M
Free CF
$18.3M
52W Change
259.9%
Annual Financials
Cash vs Debt
With $101.6M in cash and $20.6M in debt, AXGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $18.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -18.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $127.4M (2021) to $225.2M (2025), reflecting a 77% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Axogen, Inc. and its sector.